Full profile
| Also known as | Alpha-tocopherol, Mixed tocopherols |
|---|---|
| Best for | Not featured as a cognitive active; evaluated and graded out on a safety signal · Legitimate use is limited to correcting diagnosed deficiency under clinical supervision |
| Evidence grade | Graded out: evaluated and not featured (failed replication or a safety signal) |
| Studied dose range | Not recommended as a cognitive supplement. For reference: RDA is 15 mg/day; the tolerable upper limit is 1,000 mg/day of any supplemental alpha-tocopherol form, and the harm signals cluster at ≥400 IU/day, at or below the doses studied for brain benefit, so there is no clean therapeutic window for cognition. |
| Time to effect | Not applicable: no reliable cognitive benefit demonstrated in replete adults. |
| Best form | If used for diagnosed deficiency only, natural RRR-alpha-tocopherol (d-alpha) is better absorbed than synthetic all-rac; "mixed tocopherols" marketing does not resolve the safety concern. |
| Food sources | Wheat germ and vegetable oils, Nuts and seeds (almonds, sunflower seeds), Leafy greens, Avocado |
Evidence, honestly graded
Graded out on a safety veto, not an evidence-strength judgment about the nutrient itself. Frank vitamin E deficiency (rare outside malabsorption) does cause neurological harm, but that is repletion, not a nootropic effect. In replete adults the cognitive-prevention evidence is null (PREADViSE, Kryscio 2017), and the supplemental doses historically tested for brain and cardiovascular benefit carry documented safety signals: a dose-response meta-analysis linked ≥400 IU/day to increased all-cause mortality (Miller 2005), and the SELECT trial linked 400 IU/day to increased prostate cancer risk in healthy men (Klein 2011). A transparency-first brand cannot feature, as a cognitive active, a supplement whose studied "benefit" doses raise mortality and cancer risk.
See the full grading rubric (study type, replication, population match, and dose adequacy) in The Evidence Standard.
7,307 natural health products with an active licence in Health Canada's LNHPD list Vitamin E as a medicinal ingredient.
That makes Vitamin E a recognized, licensable medicinal ingredient in Canada, regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.
Side effects
- Increased bleeding / hemorrhagic-stroke risk at high doses
- Increased all-cause mortality signal at ≥400 IU/day
- Increased prostate cancer risk in healthy men at 400 IU/day
Who should avoid it or check first
- On anticoagulant or antiplatelet therapy
- Before surgery
- Elevated prostate cancer risk
- History of hemorrhagic stroke
Interactions
- Adds to bleeding risk with warfarin and other anticoagulants/antiplatelets
- May interfere with chemotherapy and radiotherapy
- May blunt some statin/niacin lipid effects
Use caution stacking with
- High-dose antioxidant stacks; do not feature vitamin E as a cognitive active
What to look for on a label
- Documented here for transparency, not a featured cognitive active. Any supplemental use should carry the ≥400 IU/day mortality and prostate-cancer safety context and the anticoagulant bleeding caution.
- The tolerable upper limit is 1,000 mg/day supplemental alpha-tocopherol; the doses studied for brain benefit sit in the harm range.
References
- Amin & Mostafa 2026, Nutrition Research: systematic review. Reviews 43 clinical studies of vitamin E and cognition. Only one of them tested a vitamin E supplement on its own; the rest measured dietary intake or multivitamins containing vitamin E, which is why an association reported at the dietary level says little about supplementing. PMID 41418497; doi:10.1016/j.nutres.2025.11.009.
- Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E (2005). Annals of Internal Medicine, 142(1):37–46High-dose vitamin E (≥400 IU/day) associated with increased all-cause mortality.
- Klein EA, Thompson IM Jr, Tangen CM, et al. (2011). JAMA, 306(14):1549–1556Vitamin E 400 IU/day increased prostate cancer risk.
- Kryscio RJ, Abner EL, Caban-Holt A, et al. (2017). JAMA Neurology, 74(5):567–573No dementia prevention from vitamin E and/or selenium.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-09-17Citation review
Added a 2026 systematic review of 43 clinical studies of vitamin E and cognition. Only one tested a vitamin E supplement on its own; the rest measured dietary intake or multivitamins containing vitamin E. That is a further reason the dietary associations cannot be read across to supplementing, and it leaves the safety veto behind this status untouched.
- 2026-07-12Graded out
Published straight into Graded Out on a safety veto. In replete adults the cognitive-prevention evidence is null (PREADViSE), and high-dose supplementation carries a documented safety signal — repletion of a true deficiency is not a nootropic effect.
See how Vitamin E compares on grade, dose, and goal in the Evidence Explorer.
